Valuation: RAPT Therapeutics, Inc.

Market Cap 179.41Cr 157.72Cr 146.82Cr 134.83Cr 253.19Cr 17TCr 256.53Cr 1.75TCr 681.59Cr 8.5TCr 673.5Cr 658.99Cr 29TCr P/E 2025 *
-
P/E 2026 * -
Enterprise Value 179.41Cr 157.72Cr 146.82Cr 134.83Cr 253.19Cr 17TCr 256.53Cr 1.75TCr 681.59Cr 8.5TCr 673.5Cr 658.99Cr 29TCr EV / Sales 2025 *
-
EV / Sales 2026 * -
Free-Float
96.87%
Yield 2025 *
-
Yield 2026 * -
1 day+0.07%
6 months+0.69%
Current year+71.30%
Current year 29.77
Extreme 29.77
58.02
1 year 8.75
Extreme 8.75
58.02
3 years 5.67
Extreme 5.6652
218.8
5 years 5.67
Extreme 5.6652
325.92
10 years 5.67
Extreme 5.6652
409.68
Manager TitleAgeSince
President - 03/03/2026
Treasurer - 03/03/2026
Director TitleAgeSince
Director/Board Member - 03/03/2026
Director/Board Member - 03/03/2026
Date Insider Type Main position Quantity % Market Cap.
03/03/26 Tender

Director

48,328 0.1744%
03/03/26 Tender

Chief Technology Officer

1,64,742 0.5945%
03/03/26 Tender

Director

59,858 0.2160%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%-.--%+335.91%-69.81% 179.41Cr
-1.82%+4.80%+54.32%+68.36% 5.73TCr
-0.27%+5.74%+40.26%+80.17% 5.5TCr
-0.74%-0.88%+4.26%+420.00% 2.32TCr
+2.76%-0.15%-18.41%-12.36% 2.26TCr
-1.13%+4.54%+22.73%-8.06% 2.05TCr
+1.57%+3.30%+27.41%-29.07% 1.76TCr
-0.10%+5.57%+38.63%+565.16% 1.57TCr
+5.29%0.00%+185.09%+332.66% 1.45TCr
+0.95%+0.85%+26.15%+185.71% 1.39TCr
Average +0.65%+1.47%+71.63%+153.28% 2.42TCr
Weighted average by Cap. +0.08%+1.92%+42.18%+137.36%

Financials

2025 *2026 *
Net sales - -
Net income - -
Net Debt - -
Logo RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Employees
60
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RAPT Stock